With the rapid advancement of the biopharmaceutical and medical device industries, the Recombinant Factor C (rFC) endotoxin detection method has emerged as an important extension and sustainable alternative to traditional Limulus Amebocyte Lysate (LAL) reagents. Owing to its non-animal origin, high specificity, and superior lot-to-lot consistency, rFC offers significant technical and ecological advantages.

From vaccine manufacturing to high-end implantable medical devices, the application scope of rFC continues to expand, with steadily increasing market demand. This transformation not only addresses the urgent need for horseshoe crab resource conservation but also reshapes the ecosystem of bacterial endotoxin testing through a more precise and sustainable technological pathway.

Global Pharmacopoeial and Regulatory Status of rFC

Europe

Pharmacopoeial Authority: European Pharmacopoeia (Ph. Eur.)

• General Chapter 2.6.32 – Bacterial Endotoxins Test Using Recombinant Factor C
  Effective January 1, 2021
  Formally adopted as an official compendial method. rFC may be used for product release testing without mandatory parallel comparison to the LAL method.
• Revisions to Monographs 0169 (Water for Injection) and 0008 (Purified Water)
  Effective April 1, 2024
  Explicitly permit the use of rFC for endotoxin testing of pharmaceutical water.

United States

Pharmacopoeial Authority: United States Pharmacopeia (USP)

• General Chapter <86> – Bacterial Endotoxins Test Using Recombinant Reagents
  Published November 2024; Official May 2025
  Incorporated as an independent non-animal–derived endotoxin testing method.

Prior to formal inclusion in USP, the U.S. FDA had already approved the first drug product released using the rFC method in 2018.

China

Pharmacopoeial Authority: Chinese Pharmacopoeia (Ch.P)

• Guideline 9251 – General Principles for the Application of the Bacterial Endotoxins Test
  2020 Edition

Mentions the recombinant Factor C method as an acceptable testing approach. Currently positioned as a guiding principle rather than a mandatory general chapter.

Other Countries

Japan, South Korea, and others

Pharmacopoeias in these countries have referenced or are actively considering the inclusion of the recombinant Factor C method as an alternative option for endotoxin testing. 

Europe has fully integrated rFC into its official pharmacopoeial framework; the United States has completed the legislative process for an independent chapter; and China has proactively advocated its use through guiding principles. This regulatory recognition is accelerating rFC’s transition from an “alternative method” to a mainstream solution.

Validation Requirements for the Recombinant Factor C Method

According to USP, Ph. Eur., and Ch.P requirements, validation of the rFC method typically includes the following parameters:

1. Standard Curve & Linearity

A strong linear relationship must be demonstrated between endotoxin concentration and fluorescence response, with a coefficient of determination (R²) ≥ 0.980.

2. Accuracy

Verified through spike recovery studies, typically requiring recovery rates within 50%–200%.

3. Precision

Assessed via repeatability studies, with a coefficient of variation (CV) generally required to be <10%.

4. Specificity

Demonstrates exclusive detection of endotoxin without cross-reactivity to β-glucans (a natural advantage of the rFC method).

5. Sensitivity & Range

Determination of the Limit of Detection (LOD) and Limit of Quantification (LOQ) to ensure coverage of product endotoxin limits.

6. Robustness

Evaluation of the impact of minor variations (e.g., incubation time, operator differences) on test results. This is often simplified depending on regulatory expectations.

7. Comparability

When replacing an existing LAL method, comparability studies must demonstrate equivalent performance (recovery 50%–200%).

Product-Specific Suitability Testing (Critical Step)

After initial method validation, product-specific suitability testing (interference testing) must be performed for each individual product or key raw material. This step is essential to ensure reliability in routine quality control testing.

Sample Pretreatment

Evaluate whether dilution or other pretreatment measures (e.g., addition of divalent cations) are required to eliminate matrix interference.

Spike Recovery Study

Add a known amount of endotoxin standard to the test sample and verify that recovery falls within 50%–200%.

Maximum Valid Dilution (MVD)

Determine the maximum dilution factor at which the sample can be tested without introducing interference.

From an operational perspective, the fluorescence microplate reader is regarded as the critical instrument, as it directly determines assay performance and result reliability. Its pyrogen-free microplates are not the same with chromogenic method.